Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
---|---|---|---|---|---|---|---|---|---|
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $4.9 | ― | 32.30% | Downgraded | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $25→$35 | ― | 15.80% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $210 | ― | 22.70% | Reiterated | ||||
Petroleo Brasileiro SA- Petrobras | BUY $18.5 | ― | 0.00% | Reiterated | Positive Outlook for Petrobras: Strategic Growth and Strong Shareholder Returns Drive Buy Rating | ||||
KE Holdings Inc. Sponsored ADR Class A | BUY $28 | ― | -12.60% | Reiterated | Miranda Zhuang Reaffirms Buy Rating on KE Holdings Inc. Amid Promising Market Conditions and Strong Performance | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $50→$74 | ― | 0.90% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $30 | ― | 7.50% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $155 | ― | 11.30% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $25→$28 | ― | 2.80% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $180 | ― | 2.80% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $206 | ― | 13.20% | Upgraded | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $570 | ― | 18.20% | Initiated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $350 | ― | 18.20% | Initiated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $250 | ― | 18.20% | Initiated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $220 | ― | 18.20% | Initiated | ||||
Texas Instruments | HOLD $215 | ― | -1.40% | Assigned | Cautious Outlook on Texas Instruments Amid Manufacturing Investments and Market Volatility | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $85 | ― | 18.20% | Initiated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $115→$83 | ― | 8.00% | Downgraded | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $23 | ― | 18.20% | Initiated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $14 | ― | 18.20% | Initiated | ||||
Zymeworks | HOLD $12 | ― | -18.50% | Reiterated | Zymeworks Hold Rating: Balancing FDA Milestones with Market Valuation and Future Risks | ||||
Replimune Group | BUY $17 | ― | -18.50% | Reiterated | Buy Recommendation for Replimune Group: Promising Developments and Clinical Results of RP1 Treatment | ||||
Rallybio | BUY $5 | ― | -16.70% | Reiterated | Rallybio's Promising Advances and Financial Projections Earn 'Buy' Rating from Analyst | ||||
Korro Bio | BUY $115 | ― | -16.70% | Reiterated | Mitchell Kapoor Reaffirms Buy Rating for Korro Bio Amid Promising Developments in KRRO-110 Treatment | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $50 | ― | 3.80% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $90→$98 | ― | 2.40% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $164 | ― | 4.90% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $180 | ― | 6.00% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $125 | ― | 4.70% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $29→$30 | ― | 4.90% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $127→$132 | ― | 5.90% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $320→$375 | ― | 1.70% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $181 | ― | 0.10% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $74→$83 | ― | 6.30% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $26→$28 | ― | 0.10% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $330→$369 | ― | 12.20% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $685→$730 | ― | 15.70% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $610 | ― | 18.20% | Initiated | ||||
Amphastar Pharmaceuticals | BUY $55 | ― | 1.70% | Initiated | Amphastar initiated with an Equal Weight at Wells Fargo | ||||
Life Time Group Holdings | BUY $29 | ― | -17.80% | Initiated | Life Time Group initiated with an Outperform at Evercore ISI | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $205→$215 | ― | 11.40% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $24→$28 | ― | 32.70% | Reiterated | ||||
Innovid | HOLD | ― | -4.70% | Downgraded | Innovid downgraded to Hold from Buy at Needham | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $37→$44 | ― | 5.80% | Assigned | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $19 | ― | 8.60% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $32 | ― | 8.60% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $178 | ― | 5.70% | Reiterated | ||||
Autodesk | BUY $350 | ― | 0.00% | Assigned | Analysts Have Conflicting Sentiments on These Technology Companies: Autodesk (NASDAQ: ADSK), NetApp (NASDAQ: NTAP) and Alkami Technology (NASDAQ: ALKT) | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $135 | ― | 24.60% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $140 | ― | 24.80% | Assigned |